Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
Advanced liver disease complicated by hepatopulmonary syndrome is a recognized complication of Gaucher disease. Macrophage-targeted, recombinant enzyme replacement therapy is effective in reversing clinical manifestations attributed to the accumulation of glycolipid-laden macrophages but it is not k...
Main Authors: | Amal El Beshlawy, Vagishwari Murugesan, Pramod Kumar Mistry, Khaled Eid |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Molecular Genetics and Metabolism Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426919300758 |
Similar Items
-
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
by: Deborah Elstein, et al.
Published: (2009-08-01) -
Imiglucerase in the treatment of Gaucher disease: a history and perspective
by: Deegan PB, et al.
Published: (2012-04-01) -
Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.
by: You-Hai Xu, et al.
Published: (2010-05-01) -
Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
by: Nathaniel Kleytman, et al.
Published: (2021-12-01) -
Enzyme replacement in Gaucher disease.
by: Ernest Beutler
Published: (2004-11-01)